Abwiz Bio Inc. is organized around development of novel monoclonal antibody development biotechnology with a current focus on novel therapeutic reagents for food allergies. The prevalence of food allergies have been dramatically increasing for the last few decades with an estimated 15 million Americans have food allergies. Signs and symptoms of food allergies range from itching, hives and diarrhea to life-threatening anaphylaxis. Work by the firm's principals suggest that histamine-releasing factor mediated activation of mast cells and basophils is required for food allergies. The company specializes in monoclonal antibody developmen, providing researcher with high-quality, high affinity, phospho specific monoclonal antibodies for flow symmetry through a stage of art rabbit antibody technology that includes a unique learning method and optimal expression system.
